Top MarketRank™ StocksTop MarketRank™Positive News SentimentPositive NewsNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $35.94 -0.38 (-1.05%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Royalty Pharma Stock (NASDAQ:RPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Royalty Pharma alerts:Sign Up Key Stats Today's Range$35.90▼$36.9950-Day Range$34.56▼$37.9152-Week Range$24.05▼$38.00Volume1.60 million shsAverage Volume4.31 million shsMarket Capitalization$20.96 billionP/E Ratio20.77Dividend Yield2.45%Price Target$48.00Consensus RatingBuy Company Overview Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Read More Royalty Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks100th Percentile Overall ScoreRPRX MarketRank™: Royalty Pharma scored higher than 100% of companies evaluated by MarketBeat, and ranked 8th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.24% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 8.24% in the coming year, from $4.49 to $4.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 21.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 21.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.43.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.57% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.42%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has been increasing its dividend for 5 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 50.87%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 18.11% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Sustainability and ESG3.7 / 5Environmental Score-2.25 Percentage of Shares Shorted4.57% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.52 News SentimentRoyalty Pharma has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Royalty Pharma this week, compared to 11 articles on an average week.Search Interest19 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Stock News Headlines1 Value Stock with Exciting Potential and 2 We Avoid5 hours ago | finance.yahoo.comRoyalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million5 hours ago | markets.businessinsider.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 25 at 2:00 AM | Timothy Sykes (Ad)Royalty Pharma PLC Acquires Royalty Interest in Amgen's Imdelltra for $885 Million | RPRX stock newsAugust 25 at 7:10 AM | gurufocus.comRoyalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 millionAugust 25 at 6:33 AM | reuters.comRoyalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 MillionAugust 25 at 6:10 AM | globenewswire.comHenry Fernandez Steps Down from Royalty Pharma's Board of DirectorsAugust 13, 2025 | globenewswire.com5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings CallAugust 13, 2025 | finance.yahoo.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $25.51 at the beginning of 2025. Since then, RPRX shares have increased by 43.1% and is now trading at $36.4950. How were Royalty Pharma's earnings last quarter? Royalty Pharma PLC (NASDAQ:RPRX) announced its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. The biopharmaceutical company earned $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a trailing twelve-month return on equity of 25.54% and a net margin of 44.23%. Read the conference call transcript. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional investors of Royalty Pharma include Vanguard Group Inc. (6.47%), State Street Corp (1.81%), Geode Capital Management LLC (1.45%) and Adage Capital Partners GP L.L.C. (1.07%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist and Rory B Riggs. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Bristol Myers Squibb (BMY), Chevron (CVX), McKesson (MCK), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW) and Invesco QQQ (QQQ). Company Calendar Record date for 6/10 Dividend5/16/2025Ex-Dividend for 6/10 Dividend5/16/2025Dividend Payable6/10/2025Last Earnings8/06/2025Record date for 9/10 Dividend8/15/2025Ex-Dividend for 9/10 Dividend8/15/2025Today8/25/2025Dividend Payable9/10/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CIK1802768 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Price Target for Royalty Pharma$48.00 High Price Target$54.00 Low Price Target$42.00 Potential Upside/Downside+32.2%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$1.73 Trailing P/E Ratio20.99 Forward P/E Ratio8.09 P/E Growth2.37Net Income$858.98 million Net Margins44.23% Pretax Margin72.19% Return on Equity25.54% Return on Assets14.11% Debt Debt-to-Equity Ratio0.74 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$2.26 billion Price / Sales9.36 Cash Flow$4.19 per share Price / Cash Flow8.66 Book Value$17.56 per share Price / Book2.07Miscellaneous Outstanding Shares583,170,000Free Float472,954,000Market Cap$21.18 billion OptionableOptionable Beta0.55 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:RPRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.